US5595886A
(en)
|
1986-01-27 |
1997-01-21 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
US6060447A
(en)
*
|
1987-05-19 |
2000-05-09 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
IE69026B1
(en)
|
1987-06-12 |
1996-08-07 |
Immuno Ag |
Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
|
US6346513B1
(en)
|
1987-06-12 |
2002-02-12 |
Baxter Trading Gmbh |
Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
|
US5629287A
(en)
*
|
1991-01-18 |
1997-05-13 |
University College London |
Depot formulations
|
US5610148A
(en)
*
|
1991-01-18 |
1997-03-11 |
University College London |
Macroscopically oriented cell adhesion protein for wound treatment
|
SE468050C
(sv)
*
|
1991-03-15 |
1998-02-11 |
Pharmacia & Upjohn Ab |
Rekombinant derivat av human faktor VIII
|
US5364771A
(en)
*
|
1992-04-07 |
1994-11-15 |
Emory University |
Hybrid human/porcine factor VIII
|
US5888974A
(en)
*
|
1992-04-07 |
1999-03-30 |
Emory University |
Hybrid human/animal factor VIII
|
US5663060A
(en)
*
|
1992-04-07 |
1997-09-02 |
Emory University |
Hybrid human/animal factor VIII
|
US5744446A
(en)
*
|
1992-04-07 |
1998-04-28 |
Emory University |
Hybrid human/animal factor VIII
|
DK53792D0
(da)
*
|
1992-04-24 |
1992-04-24 |
Novo Nordisk As |
Fremgangsmaade til fremstilling af proteiner
|
DE69333974T2
(de)
*
|
1992-10-02 |
2006-08-03 |
Genetics Institute, LLC, Cambridge |
Zusammensetzung, welche den Koagulationsfaktor VIII beinhaltet; Verfahren zu deren Herstellung und die Benutzung eines Oberflächenaktiven Stoffes als Stabilisator
|
SE9300509D0
(sv)
*
|
1993-02-16 |
1993-02-16 |
Kabi Pharmacia Ab |
Peg treatment
|
SE9301581D0
(sv)
*
|
1993-05-07 |
1993-05-07 |
Kabi Pharmacia Ab |
Protein formulation
|
SE504074C2
(sv)
*
|
1993-07-05 |
1996-11-04 |
Pharmacia Ab |
Proteinberedning för subkutan, intramuskulär eller intradermal administrering
|
SE9303601D0
(sv)
*
|
1993-11-01 |
1993-11-01 |
Kabi Pharmacia Ab |
Improved cell cultivation method and medium
|
US6288030B1
(en)
|
1993-12-22 |
2001-09-11 |
Amgen Inc. |
Stem cell factor formulations and methods
|
IL113010A
(en)
*
|
1994-03-31 |
1999-10-28 |
Pharmacia & Upjohn Ab |
Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
|
SE9403915D0
(sv)
*
|
1994-11-14 |
1994-11-14 |
Annelie Almstedt |
Process A
|
SE503424C2
(sv)
*
|
1994-11-14 |
1996-06-10 |
Pharmacia Ab |
Process för rening av rekombinant koagulationsfaktor VIII
|
US6818439B1
(en)
|
1994-12-30 |
2004-11-16 |
Chiron Corporation |
Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
|
SE9501189D0
(sv)
*
|
1995-03-31 |
1995-03-31 |
Pharmacia Ab |
Protein formulation
|
WO1997003193A1
(en)
*
|
1995-07-11 |
1997-01-30 |
Chiron Corporation |
Novel factor viii:c polypeptide analogs with altered metal-binding properties
|
SE9503380D0
(sv)
*
|
1995-09-29 |
1995-09-29 |
Pharmacia Ab |
Protein derivatives
|
US5851800A
(en)
*
|
1996-05-14 |
1998-12-22 |
Pharmacia & Upjohn Ab |
Process for producing a protein
|
DK1318198T3
(da)
*
|
1996-05-14 |
2006-07-31 |
Biovitrum Ab |
Fremgangsmåde til fremstilling af et rekombinant polypeptid under tilsætning af en inhibitor for chymotrypsin til cellekulturmediet
|
US6475725B1
(en)
|
1997-06-20 |
2002-11-05 |
Baxter Aktiengesellschaft |
Recombinant cell clones having increased stability and methods of making and using the same
|
EP1036177A1
(de)
|
1997-12-05 |
2000-09-20 |
The Immune Response Corporation |
Vektoren und gene die eine verbesserte genexpression zur folge haben
|
US7820796B2
(en)
|
1998-03-12 |
2010-10-26 |
Genetics Institute, Llc. |
Methods for producing Factor VIII proteins
|
US6797505B2
(en)
|
1998-05-27 |
2004-09-28 |
Cell Genesys, Inc. |
Recombinant AAV vectors for gene therapy of hemophilia A
|
US6221349B1
(en)
|
1998-10-20 |
2001-04-24 |
Avigen, Inc. |
Adeno-associated vectors for expression of factor VIII by target cells
|
US6200560B1
(en)
|
1998-10-20 |
2001-03-13 |
Avigen, Inc. |
Adeno-associated virus vectors for expression of factor VIII by target cells
|
US6358703B1
(en)
|
1998-12-10 |
2002-03-19 |
Bayer Corporation |
Expression system for factor VIII
|
CA2634664C
(en)
|
1999-02-22 |
2011-08-09 |
University Of Connecticut |
Novel albumin-free factor viii formulations
|
SE9901379D0
(sv)
|
1999-04-19 |
1999-04-19 |
Pharmacia & Upjohn Ab |
Receptor structures
|
AT409379B
(de)
|
1999-06-02 |
2002-07-25 |
Baxter Ag |
Medium zur protein- und serumfreien kultivierung von zellen
|
CZ303929B6
(cs)
*
|
2000-03-22 |
2013-07-03 |
Octapharma Biopharmaceuticals Gmbh |
Mutein faktoru VIII, odpovídající DNA sekvence, vektor a hostitelská bunka, farmaceutická kompozice, zpusob produkce muteinu a imortalizovaná lidská bunecná linie
|
GB0207092D0
(en)
|
2002-03-26 |
2002-05-08 |
Sod Conseils Rech Applic |
Stable pharmaceutical composition containing factor VIII
|
MXPA05000418A
(es)
|
2002-07-09 |
2005-03-23 |
Baxter Int |
Medios libres de proteina animal para cultivacion de celulas.
|
HUE058897T2
(hu)
|
2003-02-26 |
2022-09-28 |
Nektar Therapeutics |
Polimer VIII-as faktor egység konjugátumok
|
US20070026485A1
(en)
|
2003-04-09 |
2007-02-01 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
WO2005012484A2
(en)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
ES2874298T3
(es)
|
2003-09-30 |
2021-11-04 |
Univ Pennsylvania |
Clados de virus adenoasociados (AAV), secuencias, vectores que contienen el mismo, y usos de los mismos
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
DK2586456T3
(en)
|
2004-10-29 |
2016-03-21 |
Ratiopharm Gmbh |
Conversion and glycopegylation of fibroblast growth factor (FGF)
|
US20060094104A1
(en)
|
2004-10-29 |
2006-05-04 |
Leopold Grillberger |
Animal protein-free media for cultivation of cells
|
ES2821832T3
(es)
|
2004-11-12 |
2021-04-27 |
Bayer Healthcare Llc |
Modificación de FVIII dirigida al sitio
|
JP4951527B2
(ja)
|
2005-01-10 |
2012-06-13 |
バイオジェネリックス アーゲー |
糖peg化顆粒球コロニー刺激因子
|
EP1707634A1
(de)
|
2005-03-29 |
2006-10-04 |
Octapharma AG |
Verfahren zur Isolierung von rekombinant hergestellten Proteinen
|
ES2580044T3
(es)
|
2005-04-07 |
2016-08-18 |
The Trustees Of The University Of Pennsylvania |
Método de incremento de la función de un vector de AAV
|
US20070154992A1
(en)
|
2005-04-08 |
2007-07-05 |
Neose Technologies, Inc. |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
EP1739179A1
(de)
|
2005-06-30 |
2007-01-03 |
Octapharma AG |
Serumfreie stabile Transfektion und Produktion von rekombinanten humanen Proteinen in humanen Zelllinien
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
ES2790887T3
(es)
|
2006-01-04 |
2020-10-29 |
Baxalta Inc |
Medio de cultivo celular sin oligopéptidos
|
KR20080108147A
(ko)
*
|
2006-03-31 |
2008-12-11 |
백스터 인터내셔널 인코포레이티드 |
페질화된 인자 viii
|
US7982010B2
(en)
|
2006-03-31 |
2011-07-19 |
Baxter International Inc. |
Factor VIII polymer conjugates
|
US7985839B2
(en)
|
2006-03-31 |
2011-07-26 |
Baxter International Inc. |
Factor VIII polymer conjugates
|
US7645860B2
(en)
|
2006-03-31 |
2010-01-12 |
Baxter Healthcare S.A. |
Factor VIII polymer conjugates
|
WO2008011633A2
(en)
|
2006-07-21 |
2008-01-24 |
Neose Technologies, Inc. |
Glycosylation of peptides via o-linked glycosylation sequences
|
US8969532B2
(en)
|
2006-10-03 |
2015-03-03 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
|
PT2101821E
(pt)
|
2006-12-15 |
2014-10-03 |
Baxter Int |
Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
|
SI2126106T1
(en)
|
2007-02-23 |
2018-03-30 |
Sk Chemicals Co., Ltd. |
A process for the production and purification of factor VIII and its derivatives
|
CA2682897C
(en)
|
2007-04-03 |
2016-11-22 |
Biogenerix Ag |
Methods of treatment using glycopegylated g-csf
|
MX2009013259A
(es)
|
2007-06-12 |
2010-01-25 |
Novo Nordisk As |
Proceso mejorado para la produccion de azucares de nucleotidos.
|
PL2574677T3
(pl)
|
2007-12-27 |
2017-12-29 |
Baxalta GmbH |
Sposoby hodowli komórek
|
PL2257311T3
(pl)
|
2008-02-27 |
2014-09-30 |
Novo Nordisk As |
Koniugaty cząsteczek czynnika VIII
|
PT2393828T
(pt)
|
2009-02-03 |
2017-01-18 |
Amunix Operating Inc |
Polipéptidos recombinantes estendidos e composições que compreendem os mesmos
|
PT2440239T
(pt)
|
2009-06-09 |
2017-10-19 |
Prolong Pharmaceuticals Llc |
Composições de hemoglobina
|
PL2459224T3
(pl)
|
2009-07-27 |
2017-08-31 |
Baxalta GmbH |
Koniugaty białka związanego z krzepnięciem krwi
|
CN102573920B
(zh)
|
2009-07-27 |
2015-01-14 |
利普森技术有限公司 |
非凝血蛋白的糖基多唾液酸化
|
US8642737B2
(en)
|
2010-07-26 |
2014-02-04 |
Baxter International Inc. |
Nucleophilic catalysts for oxime linkage
|
JP5908401B2
(ja)
|
2009-07-27 |
2016-04-26 |
バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated |
血液凝固タンパク質複合体
|
US8809501B2
(en)
|
2009-07-27 |
2014-08-19 |
Baxter International Inc. |
Nucleophilic catalysts for oxime linkage
|
JP5813641B2
(ja)
|
2009-08-24 |
2015-11-17 |
アムニクス オペレーティング インコーポレイテッド |
凝固第ix因子組成物ならびにそれを製造および使用する方法
|
GB0915481D0
(en)
|
2009-09-04 |
2009-10-07 |
Arecor Ltd |
Stable manufacture of factor V111
|
PL3326643T3
(pl)
|
2009-12-06 |
2021-10-25 |
Bioverativ Therapeutics Inc. |
Chimeryczne i hybrydowe polipeptydy czynnika VIII-FC oraz sposoby ich zastosowania
|
WO2011095604A1
(en)
|
2010-02-04 |
2011-08-11 |
Octapharma Biopharmaceuticals Gmbh |
Half-life prolongation of proteins
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
WO2011126808A2
(en)
|
2010-03-29 |
2011-10-13 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
NZ605400A
(en)
|
2010-07-09 |
2015-05-29 |
Biogen Idec Hemophilia Inc |
Chimeric clotting factors
|
EP3508573A1
(de)
|
2010-07-09 |
2019-07-10 |
Bioverativ Therapeutics Inc. |
Systeme für faktor viii-verarbeitung und verfahren davon
|
EP3466968A1
(de)
*
|
2010-09-15 |
2019-04-10 |
Stichting Sanquin Bloedvoorziening |
Faktor-viii-varianten mit reduzierter zellulärer aufnahme
|
CN103269723B
(zh)
|
2010-12-22 |
2017-04-05 |
百深有限责任公司 |
用于偶联水溶性脂肪酸衍生物与蛋白质的材料和方法
|
CA2826316C
(en)
|
2011-02-17 |
2021-04-27 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
|
SI2717898T1
(sl)
|
2011-06-10 |
2019-07-31 |
Bioverativ Therapeutics Inc. |
Spojine prokoagulantov in metode za njihovo uporabo
|
DK3513804T3
(da)
|
2011-07-08 |
2022-06-20 |
Bioverativ Therapeutics Inc |
Kimære og hybride faktor viii-polypeptider og fremgangsmåder til anvendelse deraf
|
EP2737311B1
(de)
|
2011-07-25 |
2020-12-02 |
Bioverativ Therapeutics Inc. |
Tests zur überwachung von blutungsstörungen
|
AU2012324020A1
(en)
|
2011-12-30 |
2013-07-18 |
Grifols, S.A. |
Method for purifying Factor VIII
|
SG11201403764XA
(en)
|
2012-01-12 |
2014-07-30 |
Biogen Idec Inc |
Chimeric factor viii polypeptides and uses thereof
|
SI2802668T1
(sl)
|
2012-01-12 |
2019-01-31 |
Bioverativ Therapeutics Inc. |
Zmanjšanje imunogeničnosti proti faktorju VIII pri posameznikih, ki se zdravijo zaradi faktorja VIII
|
HUE043537T2
(hu)
|
2012-02-15 |
2019-08-28 |
Bioverativ Therapeutics Inc |
Rekombináns VIII faktor fehérjék
|
PL3564260T3
(pl)
|
2012-02-15 |
2023-03-06 |
Bioverativ Therapeutics Inc. |
Kompozycje czynnika viii oraz sposoby ich wytwarzania i stosowania
|
EP3693000B1
(de)
|
2012-06-08 |
2022-03-02 |
Bioverativ Therapeutics Inc. |
Prokoagulatorische verbindungen
|
CA2875247A1
(en)
|
2012-06-08 |
2013-12-12 |
Biogen Idec Ma Inc. |
Chimeric clotting factors
|
WO2014008480A2
(en)
|
2012-07-06 |
2014-01-09 |
Biogen Idec Ma Inc. |
Cell line expressing single chain factor viii polypeptides and uses thereof
|
NZ703366A
(en)
|
2012-07-11 |
2018-03-23 |
Amunix Operating Inc |
Factor viii complex with xten and von willebrand factor protein, and uses thereof
|
RU2500818C1
(ru)
*
|
2012-07-19 |
2013-12-10 |
Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") |
РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК рАР227, КОДИРУЮЩАЯ ПОЛИПЕПТИД РЕКОМБИНАНТНОГО ФАКТОРА VIII СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА, ЛИНИЯ КЛЕТОК Cricetulus griseus CHO 2H5 - ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ФАКТОРА VIII СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА И СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА, ОБЛАДАЮЩЕГО АКТИВНОСТЬЮ ФАКТОРА VIII
|
EP3970738A1
(de)
|
2012-07-25 |
2022-03-23 |
Bioverativ Therapeutics Inc. |
Blutfaktorüberwachungstest und verwendungen davon
|
WO2014063108A1
(en)
|
2012-10-18 |
2014-04-24 |
Biogen Idec Ma Inc. |
Methods of using a fixed dose of a clotting factor
|
EP3446700A1
(de)
|
2012-10-30 |
2019-02-27 |
Bioverativ Therapeutics Inc. |
Verfahren zur verwendung von fviii-polypeptid
|
PL2956477T3
(pl)
|
2013-02-15 |
2021-06-14 |
Bioverativ Therapeutics Inc. |
Zoptymalizowany gen czynnika viii
|
WO2014144795A1
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Factor viii polypeptide formulations
|
SG10201913874TA
(en)
|
2013-03-15 |
2020-03-30 |
Biogen Ma Inc |
Factor ix polypeptide formulations
|
WO2015012924A2
(en)
|
2013-04-29 |
2015-01-29 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
|
EP3875106A1
(de)
|
2013-08-08 |
2021-09-08 |
Bioverativ Therapeutics Inc. |
Reinigung von chimären fviii-molekülen
|
EP3033098B1
(de)
|
2013-08-14 |
2022-06-22 |
Bioverativ Therapeutics Inc. |
Rekombinante faktor-viii-proteine
|
TW202003554A
(zh)
|
2013-08-14 |
2020-01-16 |
美商百歐維拉提夫治療公司 |
因子viii-xten融合物及其用途
|
ES2900425T3
(es)
|
2013-09-25 |
2022-03-16 |
Bioverativ Therapeutics Inc |
Métodos de inactivación vírica en columna
|
EP3060242A1
(de)
|
2013-10-22 |
2016-08-31 |
DBV Technologies |
Verfahren zur behandlung von hämophilie durch induktion einer toleranz in blutfaktoren
|
EP3065769A4
(de)
|
2013-11-08 |
2017-05-31 |
Biogen MA Inc. |
Prokoagulatorische fusionsverbindung
|
EP4332839A2
(de)
|
2013-12-06 |
2024-03-06 |
Bioverativ Therapeutics Inc. |
Pharmakokinetische werkzeuge für populationen und verwendungen davon
|
CA2931848A1
(en)
|
2013-12-09 |
2015-06-18 |
Sangamo Biosciences, Inc. |
Methods and compositions for genome engineering
|
CN117106095A
(zh)
|
2014-01-10 |
2023-11-24 |
比奥贝拉蒂治疗公司 |
因子viii嵌合蛋白及其用途
|
JP6609561B2
(ja)
|
2014-02-04 |
2019-11-20 |
バイオジェン・エムエイ・インコーポレイテッド |
翻訳後修飾を濃縮するための、フロースルーモードにおける陽イオン交換クロマトグラフィーの使用
|
WO2016012595A1
(en)
*
|
2014-07-25 |
2016-01-28 |
Csl Behring Gmbh |
Improved factor viii preparations suitable for therapeutic use and processes to obtain these
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
EP3283126B1
(de)
|
2015-04-16 |
2019-11-06 |
Emory University |
Rekombinante promotoren und vektoren zur proteinexpression in leber und verwendung davon
|
BR112018002150A2
(pt)
|
2015-08-03 |
2018-09-18 |
Bioverativ Therapeutics Inc |
proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
|
US11753461B2
(en)
|
2016-02-01 |
2023-09-12 |
Bioverativ Therapeutics Inc. |
Optimized factor VIII genes
|
AU2017368328A1
(en)
|
2016-12-02 |
2019-07-18 |
Bioverativ Therapeutics Inc. |
Methods of inducing immune tolerance to clotting factors
|
CN110520150A
(zh)
|
2016-12-02 |
2019-11-29 |
比奥维拉迪维治疗股份有限公司 |
使用嵌合凝血因子治疗血友病性关节病的方法
|
CA3072334A1
(en)
|
2017-08-09 |
2019-02-14 |
Bioverativ Therapeutics Inc. |
Nucleic acid molecules and uses thereof
|
RU2020114616A
(ru)
|
2017-09-27 |
2021-10-28 |
Сайджилон Терапьютикс, Инк. |
Способы, композиции и имплантируемые элементы, содержащие активные клетки
|
JP2021512126A
(ja)
|
2018-02-01 |
2021-05-13 |
バイオベラティブ セラピューティクス インコーポレイテッド |
第viii因子を発現するレンチウイルスベクターの使用
|
US20210145889A1
(en)
|
2018-04-04 |
2021-05-20 |
Sigilon Therapeutics, Inc. |
Methods, compositions, and implantable elements comprising stem cells
|
KR20210005608A
(ko)
|
2018-04-04 |
2021-01-14 |
시질론 테라퓨틱스, 인크. |
이식 가능한 입자 및 관련 방법
|
US20190375822A1
(en)
|
2018-05-18 |
2019-12-12 |
Bioverativ Therapeutics Inc. |
Methods of treating hemophilia a
|
CN113227385A
(zh)
|
2018-08-09 |
2021-08-06 |
比奥维拉迪维治疗股份有限公司 |
核酸分子及其用于非病毒基因疗法的用途
|
UY38389A
(es)
|
2018-09-27 |
2020-04-30 |
Sigilon Therapeutics Inc |
Dispositivos implantables para terapia celular y métodos relacionados
|
CN114007637A
(zh)
|
2019-06-19 |
2022-02-01 |
比奥维拉迪维治疗股份有限公司 |
用于治疗血友病和低骨矿物质密度的重组因子viii-fc
|
CA3188420A1
(en)
|
2020-08-07 |
2022-02-10 |
Joseph Bauman |
Vesicle targeting proteins and uses of same
|
IL310997A
(en)
|
2021-08-23 |
2024-04-01 |
Bioverativ Therapeutics Inc |
Factor VIII gene optimization
|
WO2023056331A1
(en)
|
2021-09-30 |
2023-04-06 |
Bioverativ Therapeutics Inc. |
Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
|